Literature DB >> 18222042

Deciphering the lithium transcriptome: microarray profiling of lithium-modulated gene expression in human neuronal cells.

R S Seelan1, A Khalyfa, J Lakshmanan, M F Casanova, R N Parthasarathy.   

Abstract

The mechanisms underlying lithium's therapeutic efficacy in the chronic treatment of bipolar disorder are not clearly understood. Useful insights can be obtained by identifying genes that are differentially regulated during chronic lithium treatment. Toward this end, we have used microarray technology to identify mRNAs that are differentially expressed in a human neuronal cell line that has been continuously maintained in therapeutic levels of lithium for 33 days. Significantly, unlike other transcriptomes where predominantly rodent cells were used and a limited number of genes probed, we have used human cells probed with more extensive 44,000 gene microarrays. A total of 671 differentially regulated transcripts, after correcting for false discovery rates, were identified, of which 347 and 324, respectively, were found to be up- and downregulated. Peroxiredoxin 2 (PRDX2), an antioxidant enzyme, was the most upregulated while tribbles homolog 3 (TRB3), a pro-apoptotic protein, was the most downregulated, implying a beneficial effect of lithium on neuronal cells. Several of the most highly regulated genes are novel, uncharacterized and encode proteins of unknown function. Differentially expressed genes associated with phosphoinositide metabolism include those encoding phosphatidyl inositol 4-phosphate 5-kinase type II alpha (PIP5K2A), WD repeat domain, phosphoinositide interacting 1 protein (WIPI49), tribbles homolog 3 (TRB3) and sorting nexin 14 (SNX14). A protein interactome using some of the saliently regulated genes identified protein kinase C (PKC) as a major target for lithium action while a global analysis of all 671 differentially expressed genes identified the mitogen-activated protein kinase pathway as the most regulated. The list of highly regulated genes, besides encoding putative targets for antimanic agents, should prove useful in defining novel pathways, or to better understand the mechanisms, underlying the mood stabilization process.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18222042     DOI: 10.1016/j.neuroscience.2007.10.045

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  36 in total

1.  Inositol-related gene knockouts mimic lithium's effect on mitochondrial function.

Authors:  Lilach Toker; Yuly Bersudsky; Inbar Plaschkes; Vered Chalifa-Caspi; Gerard T Berry; Roberto Buccafusca; Dieder Moechars; R H Belmaker; Galila Agam
Journal:  Neuropsychopharmacology       Date:  2013-08-08       Impact factor: 7.853

Review 2.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

3.  Increased peripheral blood expression of electron transport chain genes in bipolar depression.

Authors:  Robert D Beech; Lori Lowthert; Janine J Leffert; Portia N Mason; Mary M Taylor; Sheila Umlauf; Aiping Lin; Ji Young Lee; Kathleen Maloney; Anjana Muralidharan; Boris Lorberg; Hongyu Zhao; Samuel S Newton; Shrikant Mane; C Neill Epperson; Rajita Sinha; Hilary Blumberg; Zubin Bhagwagar
Journal:  Bipolar Disord       Date:  2010-12       Impact factor: 6.744

4.  Mood stabilizing drugs regulate transcription of immune, neuronal and metabolic pathway genes in Drosophila.

Authors:  L Herteleer; L Zwarts; K Hens; D Forero; J Del-Favero; P Callaerts
Journal:  Psychopharmacology (Berl)       Date:  2016-02-06       Impact factor: 4.530

Review 5.  Response to treatment in bipolar disorder.

Authors:  Cristiana Cruceanu; Martin Alda; Guy Rouleau; Gustavo Turecki
Journal:  Curr Opin Psychiatry       Date:  2011-01       Impact factor: 4.741

6.  A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder.

Authors:  Roy H Perlis; Jordan W Smoller; Manuel A R Ferreira; Andrew McQuillin; Nick Bass; Jacob Lawrence; Gary S Sachs; Vishwajit Nimgaonkar; Edward M Scolnick; Hugh Gurling; Pamela Sklar; Shaun Purcell
Journal:  Am J Psychiatry       Date:  2009-05-15       Impact factor: 18.112

7.  Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Authors:  Alessio Squassina; Mirko Manchia; Maria Del Zompo
Journal:  Hum Genomics Proteomics       Date:  2010-08-03

8.  Effect of mood stabilizers on gene expression in lymphoblastoid cells.

Authors:  Hiroko Sugawara; Kazuya Iwamoto; Miki Bundo; Mizuho Ishiwata; Junko Ueda; Chihiro Kakiuchi; Jun Ishigooka; Tadafumi Kato
Journal:  J Neural Transm (Vienna)       Date:  2009-12-01       Impact factor: 3.575

Review 9.  The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis.

Authors:  Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Bipolar Disord       Date:  2009-06       Impact factor: 6.744

10.  Lithium: a key to the genetics of bipolar disorder.

Authors:  Cristiana Cruceanu; Martin Alda; Gustavo Turecki
Journal:  Genome Med       Date:  2009-08-19       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.